Northwest Biotherapeutics (NWBO) Free Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 21.16% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 45.09% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 80.69% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -4.45% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 8.92% |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - | 16.75% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.75% |
| Mar 31, 2026 | -0.17% |
| Dec 31, 2025 | -12.49% |
| Sep 30, 2025 | 4.91% |
| Jun 30, 2025 | 22.89% |
| Mar 31, 2025 | 9.95% |
| Dec 31, 2024 | -16.54% |
| Sep 30, 2024 | 4.66% |
| Jun 30, 2024 | -26.30% |
| Mar 31, 2024 | 2.19% |
| Dec 31, 2023 | -9.42% |
| Sep 30, 2023 | -11.83% |
| Jun 30, 2023 | -19.03% |
| Mar 31, 2023 | -18.26% |
| Dec 31, 2022 | -21.80% |
| Sep 30, 2022 | -36.31% |
| Jun 30, 2022 | -15.48% |
| Mar 31, 2022 | -10.13% |
| Dec 31, 2021 | 3.35% |
| Sep 30, 2021 | -33.78% |